Titan Pharmaceuticals, Inc.
TTNP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 50% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -6,660% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -7,900% |
| EPS Diluted | -0.57 | -0.65 | -0.62 | -0.88 |
| % Growth | 12.3% | -4.8% | 29.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |